GO
Loading...

Amgen Misses Earnings Views; Revenue Beats Forecasts

Amgen reported a 1.1% increase in fourth-quarter profit on Thursday, helped by solid growth in sales of its anemia treatments.

The world's largest biotechnology company posted a net profit of $833 million, or 71 cents a share, compared with $824 million, or 66 cents a share, a year ago.

Excluding items, but including a cost of 3 cents a share for a collaboration announced earlier this year, Amgen earned 90 cents a share. The company missed analysts' forecasts.

Total revenue for the quarter rose 17% to $3.8 billion, led by a 27% jump to $1.1 billion in sales of Aranesp, used to treat anemia in cancer and kidney dialysis patients. Analysts were expecting revenue of $3.7 billion.

"It's a solid revenue number," Geoff Porges, a senior biotech analyst at Sanford Bernstein, told CNBC. "R&D is where the EPS miss came from."

Looking ahead to 2007, Amgen said it expects to earn $4.30 to $4.50, excluding items.

Epogen, an earlier version of Aranesp, saw sales rise 6% to $661 million.

Sales of Neulasta and Neupogen, used to boost white blood cells in chemotherapy patients, rose 10% to just over $1 billion.

Sales of Enbrel for arthritis and the skin condition psoriasis rose 18% to $792 million.

Amgen's new colon cancer drug Vectibix had sales of $39 million in its first full quarter on the market.

Amgen shares fell about 13% in 2006, mirroring the performance of rival biotech giant Genentech , but lagging the broader American Stock Exchange Biotech Index, which was up nearly 11% last year.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Michelle Girard, RBS chief U.S. economist, and Michael Hanson, Bank of America Merrill Lynch, provide their take on interest rates ahead of Fed Chair Janet Yellen's first appearance at Jackson Hole, Wyo. The stock market is more optimistic right now while the bond market is more nervous about the longer run, says Hanson.

  • Michelle Girard, RBS chief U.S. economist, and Michael Hanson, Bank of America Merrill Lynch, share their thoughts on the Fed's easy money policy.

  • Jim Cramer talks with Phil Rykhoek, the president and CEO of Denbury Resources to find out about his company's prospects.